Company intelligence / Profile preview

BioGene Australia

Brisbane, Queensland, Australia

Ownership: Private

Overview

BioGene Australia is a Brisbane-based biotechnology company operating as a wholly-owned subsidiary of Texas-based BioGene Therapeutics. The company is focused on developing innovative gene-based therapies and treatments for metabolic health, specifically targeting the global diabetes and obesity crisis. Its lead research centers on 'Smart-siRNAs' designed to inhibit protein tyrosine phosphatase 1B (PTP1B) in the brain, delivered non-invasively via a proprietary bioresponsive lipid nanoparticle (bLNP) vector and a nose-to-brain Sol-Gel nasal spray platform. Additionally, the company is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments.

Modalities: Small interfering RNABiologicGene therapy
Industry: Biotech

Partnerships

University of Queensland

Beyond the preview

Go deeper on BioGene Australia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioGene Australia.

Explore the full profile